Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Cabazitaxel—a key therapeutic option in prostate cancer

Nature Reviews Urology volume 12, pages 312–313 (2015)Cite this article

Subjects

Treatment with cabazitaxel is associated with improved survival in patients with metastatic castration-resistant prostate cancer. Bahl et al. recently reported that patient-reported quality-of-life metrics were stable—with a trend towards improvements with increasing numbers of treatment cycles—in 112 patients treated with cabazitaxel in the UK.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bahl, A. et al. Final quality of life and safety data for patients with mCRPC treated with cabazitaxel in the UK Early Access Programme (NCT01254279). BJU Int. http://dx.doi.org/10.1111/bju.13069.

  2. Omlin, A. et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur. Urol. 64, 300–306 (2013).

    Article  Google Scholar 

  3. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 1755–1756 (2014).

    Article  Google Scholar 

  4. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    Article  CAS  Google Scholar 

  5. Bianchini, D. et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur. J. Cancer 50, 78–84 (2014).

    Article  CAS  Google Scholar 

  6. Loriot, Y. et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol. 24, 1807–1812 (2013).

    Article  CAS  Google Scholar 

  7. de Bono, J. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376, 1147–1154 (2010).

    Article  CAS  Google Scholar 

  8. de Leeuw, R. et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin. Cancer Res. 21, 795–807 (2015).

    Article  CAS  Google Scholar 

  9. Pezaro, C. J. et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. 66, 459–465 (2014).

    Article  CAS  Google Scholar 

  10. Clark, M., Harris, N., Griebsch, I., Kaschinski, D. & Copley-Merriman, C. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual. Life Outcomes 12, 104 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK

    Anuradha Jayaram & Gerhardt Attard

Authors
  1. Anuradha Jayaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhardt Attard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhardt Attard.

Ethics declarations

Competing interests

G.A. declares that he has received consulting fees from Astellas, Janssen–Cilag, Millennium Pharmaceuticals, Novartis, Sanofi–Aventis and Veridex, lecture fees from Ipsen, Janssen–Cilag, and Sanofi–Aventis, and grant support from AstraZeneca and Janssen. G.A. is on the Institute of Cancer Research rewards to inventors list of abiraterone acetate. Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. A.J. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jayaram, A., Attard, G. Cabazitaxel—a key therapeutic option in prostate cancer. Nat Rev Urol 12, 312–313 (2015). https://doi.org/10.1038/nrurol.2015.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2015.98

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing